PLIN1在原发性腹膜后脂肪肉瘤组织中的表达及与阿帕替尼疗效的相关性

Expression of perilipin-1 gene in primary retroperitoneal liposarcoma and its correlation with the therapeutic effect of apatinib

目的:探讨原发性腹膜后脂肪肉瘤中脂滴包被蛋白基因(perilipin-1,PLIN1)的蛋白表达及其与甲磺酸阿帕替尼疗效的相关性。方法:采用免疫组化SABC法检测36例原发性腹膜后脂肪肉瘤及20例脂肪瘤组织中PLIN1蛋白的表达,分析PLIN1蛋白与甲磺酸阿帕替尼疗效的关系。结果:PLIN1蛋白在原发性腹膜后脂肪肉瘤和脂肪瘤组织中表达阳性率分别为19.44%(7/36)、70.00%(14/20),二者阳性率比较有显著性差异(P <0.05)。不同类型脂肪肉瘤中,分化较差者阳性率明显低于分化较好者(P <0.05)。PLIN1蛋白表达在原发者与复发者之间的差异无统计学意义(P> 0.05)。PLIN1蛋白与患者年龄、性别及肿瘤大小无相关性。PLIN1蛋白低表达组患者口服甲磺酸阿帕替尼的疗效优于高表达组,原发性腹膜后脂肪肉瘤中PLIN1蛋白表达与疗效呈负相关(P <0.05)。结论:PLIN1蛋白与原发性腹膜后脂肪肉瘤的发生发展、分化程度有关,可作为判断原发性腹膜后脂肪肉瘤分化程度及恶性程度的参考指标之一,但与肿瘤复发无关。PLIN1蛋白表达情况可作为口服甲磺酸阿帕替尼靶向治疗的生物学参考靶标。

Objective:To investigate the expression of the gene protein perilipin-1(PLIN1) in primary retroperitoneal liposarcoma and its correlation with the therapeutic effect of apatinib. Methods:36 cases of primary retroperitoneal liposarcoma and 20 cases of lipoma were detected by immunohistochemical SABC.The relationship was analyzed between the therapeutic efficacy of PLIN1 protein and apatinib. Results:PLIN1 protein expressed 19.44%(7/36) positive rate and 70.00%(14/20) positive rate in primary retroperitoneal liposarcoma and lipoma respectively,and the positive rate was significantly different in the tissues ( P <0.05).PLIN1 protein had no correlation with age,gender and tumor size of the patient.Patients with low expression of PLIN1 protein had better efficacy than patients with high expression group in the oral treatment of apatinib,and the expression of PLIN1 protein in primary retroperitoneal liposarcoma was negatively correlated with the efficacy ( P <0.05). Conclusion:PLIN1 protein is related to the development and differentiation of primary retroperitoneal liposarcoma.It can be used as one of the reference indicators to determine the degree of differentiation and malignant degree of primary retroperitoneal liposarcoma,but it has nothing to do with the recurrence of tumors.PLIN1 protein expression can be used as a biological reference target for the targeted treatment of apatinib.